175 related articles for article (PubMed ID: 20053802)
1. Abrupt regression of a meningioma after discontinuation of cyproterone treatment.
Gonçalves AM; Page P; Domigo V; Méder JF; Oppenheim C
AJNR Am J Neuroradiol; 2010 Sep; 31(8):1504-5. PubMed ID: 20053802
[TBL] [Abstract][Full Text] [Related]
2. Regression of meningiomas after discontinuation of cyproterone acetate in a transsexual patient.
Cebula H; Pham TQ; Boyer P; Froelich S
Acta Neurochir (Wien); 2010 Nov; 152(11):1955-6. PubMed ID: 20811919
[No Abstract] [Full Text] [Related]
3. Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study.
Weill A; Nguyen P; Labidi M; Cadier B; Passeri T; Duranteau L; Bernat AL; Yoldjian I; Fontanel S; Froelich S; Coste J
BMJ; 2021 Feb; 372():n37. PubMed ID: 33536184
[TBL] [Abstract][Full Text] [Related]
4. [Cyproterone acetate and meningioma: The latest findings].
Schmutz JL
Ann Dermatol Venereol; 2018 May; 145(5):390-391. PubMed ID: 29703641
[No Abstract] [Full Text] [Related]
5. Probable Drug-Related Meningioma Detected During the Course of Medication Review Services.
Alderman CP
Consult Pharm; 2016 Sep; 31(9):500-4. PubMed ID: 27636874
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of the association between cyproterone acetate and intracranial meningiomas.
Lee KS; Zhang JJY; Kirollos R; Santarius T; Nga VDW; Yeo TT
Sci Rep; 2022 Feb; 12(1):1942. PubMed ID: 35121790
[TBL] [Abstract][Full Text] [Related]
7. Cyproterone acetate and risk of meningioma: a nationwide cohort study.
Mikkelsen AP; Greiber IK; Scheller NM; Hilden M; Lidegaard Ø
J Neurol Neurosurg Psychiatry; 2022 Feb; 93(2):222-223. PubMed ID: 34187864
[No Abstract] [Full Text] [Related]
8. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy.
Gazzeri R; Galarza M; Gazzeri G
N Engl J Med; 2007 Dec; 357(23):2411-2. PubMed ID: 18057351
[No Abstract] [Full Text] [Related]
9. Preliminary report of patients with meningiomas exposed to Cyproterone Acetate, Nomegestrol Acetate and Chlormadinone Acetate - Monocentric ongoing study on progestin related meningiomas.
Devalckeneer A; Aboukais R; Bourgeois P; De Witte O; Racape J; Caron S; Perbet R; Maurage CA; Lejeune JP
Clin Neurol Neurosurg; 2021 Nov; 210():106959. PubMed ID: 34592677
[TBL] [Abstract][Full Text] [Related]
10. Presentation of a meningioma in a transwoman after nine years of cyproterone acetate and estradiol intake: case report and literature review.
Mancini I; Rotilio A; Coati I; Seracchioli R; Martelli V; Meriggiola MC
Gynecol Endocrinol; 2018 Jun; 34(6):456-459. PubMed ID: 29105524
[TBL] [Abstract][Full Text] [Related]
11. First case of cyproterone acetate induced multiple meningiomas in identical female twins: A case report.
Batchinsky-Parrou V; Barraud S; Kleiber JC; Litre F
Neurochirurgie; 2022 Apr; 68(3):323-326. PubMed ID: 33989640
[TBL] [Abstract][Full Text] [Related]
12. Meningiomas and cyproterone acetate: a retrospective, monocentric cohort of 388 patients treated by surgery or radiotherapy for intracranial meningioma.
Samarut E; Lugat A; Amelot A; Scharbarg E; Hadjadj S; Primot C; Loussouarn D; Thillays F; Buffenoir K; Cariou B; Drui D; Roualdes V
J Neurooncol; 2021 Mar; 152(1):115-123. PubMed ID: 33392938
[TBL] [Abstract][Full Text] [Related]
13. Opposed evolution of the osseous and soft parts of progestin-associated osteomeningioma after progestin intake discontinuation.
Florea SM; Passeri T; Abbritti R; Bernat AL; Fontanel S; Yoldjian I; Funck-Brentano T; Weill A; Mandonnet E; Froelich S
J Neurosurg; 2023 Oct; 139(4):944-952. PubMed ID: 36883659
[TBL] [Abstract][Full Text] [Related]
14. Atypical evolution of meningiomatosis after discontinuation of cyproterone acetate: clinical cases and histomolecular characterization.
Passeri T; Giammattei L; Le Van T; Abbritti R; Perrier A; Wong J; Bourneix C; Polivka M; Adle-Biassette H; Bernat AL; Masliah-Planchon J; Mandonnet E; Froelich S
Acta Neurochir (Wien); 2022 Jan; 164(1):255-263. PubMed ID: 34613529
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience.
Malaize H; Samoyeau T; Zanello M; Roux A; Benzakoun J; Peeters S; Zah-Bi G; Edjlali M; Tauziede-Espariat A; Dezamis E; Parraga E; Chrétien F; Varlet P; Plu-Bureau G; Oppenheim C; Pallud J
J Neurooncol; 2021 Apr; 152(2):279-288. PubMed ID: 33449307
[TBL] [Abstract][Full Text] [Related]
16. Estrogen and Progesterone Therapy and Meningiomas.
Hage M; Plesa O; Lemaire I; Raffin Sanson ML
Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34935947
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous regression of meningiomas after interruption of nomegestrol acetate: a series of three patients.
Passeri T; Champagne PO; Bernat AL; Hanakita S; Salle H; Mandonnet E; Froelich S
Acta Neurochir (Wien); 2019 Apr; 161(4):761-765. PubMed ID: 30783806
[TBL] [Abstract][Full Text] [Related]
18. Rapid growth and regression of intracranial meningiomas in lymphangioleiomyomatosis: case report.
Pozzati E; Zucchelli M; Schiavina M; Contini P; Foschini MP
Surg Neurol; 2007 Dec; 68(6):671-674. PubMed ID: 17586005
[TBL] [Abstract][Full Text] [Related]
19. Radiological evolution of progestogen-induced meningioma: A monocentric retrospective study.
Ahmed-Khalifa T; Gillet R; Blonski M; Rech F; Fresse A; Gillet P; Taillandier L; Petitpain N
Fundam Clin Pharmacol; 2023 Aug; 37(4):868-878. PubMed ID: 36692232
[TBL] [Abstract][Full Text] [Related]
20. Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome.
Graillon T; Boissonneau S; Appay R; Boucekine M; Peyrière H; Meyer M; Farah K; Albarel F; Morange I; Castinetti F; Brue T; Fuentes S; Figarella-Branger D; Cuny T; Dufour H
Neurochirurgie; 2021 Nov; 67(6):556-563. PubMed ID: 33989642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
